Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 1/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.39 |
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | PNMT | P11086 | 2/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.32 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27886393 | 0.83 | PNMT (0.41) | IDO1CYP3A4PNMTTAAR1ALDH1A1 | |
| SCHEMBL5158103 | 0.82 | CYP4F2 (0.42) | CYP4F2CYP4A11IDO1CYP3A4PNMT | |
| SCHEMBL30797232 | 0.78 | TRPA1 (0.38) | CYP4F2CYP4A11ALDH1A1TRPA1TSHR | |
| SCHEMBL29413271 | 0.78 | IDO1 (0.58) | CYP4F2CYP4A11IDO1PNMTTAAR1 | |
| SCHEMBL10128 | 0.78 | IDO1 (0.58) | CYP4F2CYP4A11IDO1PNMTTAAR1 | |
| SCHEMBL11484838 | 0.78 | TRPA1 (0.38) | CYP4F2CYP4A11ALDH1A1TRPA1TSHR | |
| SCHEMBL5085456 | 0.77 | IDO1 (0.37) | IDO1CYP3A4PNMTTAAR1SIGMAR1 | |
| SCHEMBL2951140 | 0.77 | TRPA1 (0.41) | IDO1CYP3A4PNMTTAAR1ALDH1A1 | |
| SCHEMBL6113228 | 0.77 | RECQL (0.42) | IDO1CYP3A4PNMTTAAR1TSHR | |
| SCHEMBL1964765 | 0.76 | IDO1 (0.56) | CYP4F2CYP4A11IDO1PNMTTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2491035-B1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES INC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9161934-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-10-20 | — | — | US | disclosed |
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2015-05-07 | — | — | US | disclosed |
| US-8962652-B2 | Derivatives of purine or deazapurine useful for the treatment of (inter alia) viral infections | GILEAD SCIENCES, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2014-05-08 | — | — | US | disclosed |
| US-8507507-B2 | Modulators of toll-like receptors | GILEAD SCIENCES, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2491035-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | Gilead Sciences, Inc. (US) | 2012-08-29 | — | — | EP | disclosed |
| WO-2011049825-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | WO | disclosed |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | GILEAD SCIENCES, INC. (US) | 2011-04-28 | — | — | US | disclosed |
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2005-03-24 | — | — | US | disclosed |
| EP-0594019-B1 | 1-Biphenylmethyl-pyridone derivatives, their preparation and their use as angiotensin II antagonistes | BAYER AG (DE) | 2000-02-23 | — | — | EP | disclosed |
| US-5863930-A | ATHEROSCLEROSIS TREATMENT FORMED BY REACTION OF PYRIDONES WITH BIPHENYLMETHYL HALOGEN | BAYER AKTIENGESELLSCHAFT (DE) | 1999-01-26 | — | — | US | disclosed |
| CN-1040435-C | Trisubstituted biphenyls | BAYER AG (DE) | 1998-10-28 | — | — | CN | disclosed |
| US-5596006-A | ANTIHYPERTENSIVE, ANTIATHEROSCLEROTIC AGENTS | BAYER AKTIENGESELLSCHAFT (DE) | 1997-01-21 | — | — | US | disclosed |
| CN-1089260-A | Trisubstituted biphenyls | BAYER AG (DE) | 1994-07-13 | — | — | CN | disclosed |
| EP-0594019-A1 | Trisubstituted biphenyl as angiotensin II antagonistes | BAYER AG (DE) | 1994-04-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065195-A1 | Oxadiazolyl-biphenylcarboxamides and their use as p38 kinase inhibitors | MAPK3, MAPK1, MAPKAPK3 | CYP4F2 962/4885CYP4A11 675/4885IDO1 972/4885 |
| US-20150126509-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | CYP4F2 3053/4885CYP4A11 3352/4885IDO1 470/4885 |
| US-20140128389-A1 | DERIVATIVES OF PURINE OR DEAZAPURINE USEFUL FOR THE TREATMENT OF (INTER ALIA) VIRAL INFECTIONS | ENTPD5, MAVS, TPMT | CYP4F2 3053/4885CYP4A11 3352/4885IDO1 470/4885 |
| US-20110098248-A1 | MODULATORS OF TOLL-LIKE RECEPTORS | TLR3, TLR6, TLR1 | CYP4F2 4291/4885CYP4A11 4411/4885IDO1 3160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.